FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107845557> ?p ?o ?g. }

• W2107845557 abstract "To compare clinical and health-related quality of life (HRQoL) outcomes between children and adolescents with ADHD treated with OROS® MPH, using data from two large similarly-designed multicenter, prospective, open-label, single-arm, non-interventional studies.Pooled analysis (42603ATT4037, 42603 - ATT - 4001) including patients (6 to 18 years) with a confirmed diagnosis of ADHD. Patients were treated with OROS® MPH for 12 weeks; ADHD symptoms, functioning, HRQoL, safety and tolerability parameters were assessed.822 patients (583 children [6-12 years], 239 adolescents [13-18 years]) were included in the pooled analysis. Mean daily OROS® MPH starting doses in the child and adolescent subgroups were 29.0 ± 11.7 and 37.6 ± 15.6 mg, respectively (p < 0.001). At study end (week 12), the overall mean daily dose was 35.5 ± 14.0 mg, with children and adolescents receiving 32.8 ± 12.7 and 42.0 ± 15.1 mg/day, respectively (p < 0.001). Significant (p < 0.0001: overall population, children, adolescents) symptomatic, functional and HRQoL improvements were observed from baseline to study end using the Conners' Parents Rating Scale (overall: 29.2 ± 10.7 [baseline] to 19.3 ± 11.3 [endpoint]), Children's Global Assessment Scale (overall: 58.5 ± 14.5 [baseline] to 69.6 ± 16.1 [endpoint]), and ILC-LQ0-28. At week 12, between-age group differences were seen in the individual ILC-LQ0-28 parameters: school performance (p = 0.001 [parents' assessment], p = 0.032 [childrens' assessment]), global QoL (p = 0.012 [parents']) and interests and hobbies (p = 0.023 [childrens']). Treating physician's planned continued use of OROS® MPH in 76.9%, 86.0% and 79.3% of children, adolescents and the total population, respectively, at study end (p = 0.029 between-age subgroups). 195 of 822 patients (23.7%) experienced at least one treatment-emergent adverse event; most commonly reported AEs in the total group (≥4%) were insomnia (7.2%), anorexia (4.3%) and involuntary muscle contractions (4.1%). No clinically relevant changes in body weight or vital signs were observed.Clinically relevant differences between children and adolescents with ADHD are present. Adolescents appeared to have a lower health related quality of life and functioning compared to children at baseline, however, they were able to reach comparable ratings at endpoint for most items. Similarly, burden of disease decreased in patients and their carers. OROS MPH was generally safe and well tolerated." @default.
• W2107845557 created "2016-06-24" @default.
• W2107845557 creator A5014053073 @default.
• W2107845557 creator A5023110202 @default.
• W2107845557 creator A5023280553 @default.
• W2107845557 creator A5027696640 @default.
• W2107845557 creator A5032172202 @default.
• W2107845557 creator A5043146921 @default.
• W2107845557 creator A5074778675 @default.
• W2107845557 date "2011-07-26" @default.
• W2107845557 modified "2023-10-17" @default.
• W2107845557 title "Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?" @default.
• W2107845557 cites W1514128735 @default.
• W2107845557 cites W1586258382 @default.
• W2107845557 cites W1978822116 @default.
• W2107845557 cites W1986046877 @default.
• W2107845557 cites W1989444430 @default.
• W2107845557 cites W2003911018 @default.
• W2107845557 cites W2006601420 @default.
• W2107845557 cites W2013986318 @default.
• W2107845557 cites W2016496786 @default.
• W2107845557 cites W2016797741 @default.
• W2107845557 cites W2016995778 @default.
• W2107845557 cites W2029533897 @default.
• W2107845557 cites W2032535633 @default.
• W2107845557 cites W2062714266 @default.
• W2107845557 cites W2070136850 @default.
• W2107845557 cites W2075895014 @default.
• W2107845557 cites W2078304059 @default.
• W2107845557 cites W2086188333 @default.
• W2107845557 cites W2091029144 @default.
• W2107845557 cites W2098399548 @default.
• W2107845557 cites W2114776324 @default.
• W2107845557 cites W2121519528 @default.
• W2107845557 cites W2123583621 @default.
• W2107845557 cites W2124820904 @default.
• W2107845557 cites W2132430593 @default.
• W2107845557 cites W2137706707 @default.
• W2107845557 cites W2152035718 @default.
• W2107845557 cites W2152944975 @default.
• W2107845557 cites W2161957029 @default.
• W2107845557 cites W2165304034 @default.
• W2107845557 cites W3021230114 @default.
• W2107845557 doi "https://doi.org/10.1186/1753-2000-5-26" @default.
• W2107845557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3162502" @default.
• W2107845557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21791096" @default.
• W2107845557 hasPublicationYear "2011" @default.
• W2107845557 type Work @default.
• W2107845557 sameAs 2107845557 @default.
• W2107845557 citedByCount "15" @default.
• W2107845557 countsByYear W21078455572012 @default.
• W2107845557 countsByYear W21078455572014 @default.
• W2107845557 countsByYear W21078455572016 @default.
• W2107845557 countsByYear W21078455572017 @default.
• W2107845557 countsByYear W21078455572018 @default.
• W2107845557 countsByYear W21078455572021 @default.
• W2107845557 countsByYear W21078455572022 @default.
• W2107845557 crossrefType "journal-article" @default.
• W2107845557 hasAuthorship W2107845557A5014053073 @default.
• W2107845557 hasAuthorship W2107845557A5023110202 @default.
• W2107845557 hasAuthorship W2107845557A5023280553 @default.
• W2107845557 hasAuthorship W2107845557A5027696640 @default.
• W2107845557 hasAuthorship W2107845557A5032172202 @default.
• W2107845557 hasAuthorship W2107845557A5043146921 @default.
• W2107845557 hasAuthorship W2107845557A5074778675 @default.
• W2107845557 hasBestOaLocation W21078455571 @default.
• W2107845557 hasConcept C118552586 @default.
• W2107845557 hasConcept C126322002 @default.
• W2107845557 hasConcept C138496976 @default.
• W2107845557 hasConcept C15744967 @default.
• W2107845557 hasConcept C159110408 @default.
• W2107845557 hasConcept C187212893 @default.
• W2107845557 hasConcept C197934379 @default.
• W2107845557 hasConcept C203092338 @default.
• W2107845557 hasConcept C2778375690 @default.
• W2107845557 hasConcept C2779951463 @default.
• W2107845557 hasConcept C2780783007 @default.
• W2107845557 hasConcept C2908647359 @default.
• W2107845557 hasConcept C535046627 @default.
• W2107845557 hasConcept C557119937 @default.
• W2107845557 hasConcept C71924100 @default.
• W2107845557 hasConcept C83849319 @default.
• W2107845557 hasConcept C99454951 @default.
• W2107845557 hasConceptScore W2107845557C118552586 @default.
• W2107845557 hasConceptScore W2107845557C126322002 @default.
• W2107845557 hasConceptScore W2107845557C138496976 @default.
• W2107845557 hasConceptScore W2107845557C15744967 @default.
• W2107845557 hasConceptScore W2107845557C159110408 @default.
• W2107845557 hasConceptScore W2107845557C187212893 @default.
• W2107845557 hasConceptScore W2107845557C197934379 @default.
• W2107845557 hasConceptScore W2107845557C203092338 @default.
• W2107845557 hasConceptScore W2107845557C2778375690 @default.
• W2107845557 hasConceptScore W2107845557C2779951463 @default.
• W2107845557 hasConceptScore W2107845557C2780783007 @default.
• W2107845557 hasConceptScore W2107845557C2908647359 @default.
• W2107845557 hasConceptScore W2107845557C535046627 @default.
• W2107845557 hasConceptScore W2107845557C557119937 @default.
• W2107845557 hasConceptScore W2107845557C71924100 @default.
• W2107845557 hasConceptScore W2107845557C83849319 @default.
• W2107845557 hasConceptScore W2107845557C99454951 @default.

• next